# Andrea Biondi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andrea-biondi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 60,296 |
| Field | Acute Lymphoblastic Leukemia research |
| h-index | 119 |
| i10-index | 587 |
| Last Known Institution | Istituti di Ricovero e Cura a Carattere Scientifico |
| OpenAlex ID | https://openalex.org/A5051520180 |
| ORCID iD | https://orcid.org/0000-0002-6757-6173 |
| Works | 1,225 |

## Researcher papers

- [Autoantibodies against type I IFNs in patients with life-threatening COVID-19](https://scholariq.org/papers/autoantibodies-against-type-i-ifns-in-patients-with-life-threatening-covid-19/)
- [Inborn errors of type I IFN immunity in patients with life-threatening COVID-19](https://scholariq.org/papers/inborn-errors-of-type-i-ifn-immunity-in-patients-with-life-threatening-covid-19/)
- [Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease](https://scholariq.org/papers/standardized-rt-pcr-analysis-of-fusion-gene-transcripts-from-chromosome/)
- [Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study](https://scholariq.org/papers/molecular-response-to-treatment-redefines-all-prognostic-factors-in-children-and/)
- [A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial](https://scholariq.org/papers/a-treatment-protocol-for-infants-younger-than-1-year-with-acute-lymphoblastic/)
- [Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths](https://scholariq.org/papers/autoantibodies-neutralizing-type-i-ifns-are-present-in-4-of-uninfected/)
- [Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion.](https://scholariq.org/papers/transplacental-chemical-exposure-and-risk-of-infant-leukemia-with-mll-gene/)
- [Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19](https://scholariq.org/papers/immunopathological-signatures-in-multisystem-inflammatory-syndrome-in-children/)
- [Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients](https://scholariq.org/papers/treatment-of-graft-versus-host-disease-with-mesenchymal-stromal-cells-a-phase-i/)
- [The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies](https://scholariq.org/papers/the-risk-of-covid-19-death-is-much-greater-and-age-dependent-with-type-i-ifn/)
- [Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial](https://scholariq.org/papers/tocilizumab-for-patients-with-covid-19-pneumonia-the-single-arm-tocivid-19/)

## Researcher topics

- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [Childhood Cancer Survivors' Quality of Life](https://scholariq.org/topics/childhood-cancer-survivors-quality-of-life/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [Istituti di Ricovero e Cura a Carattere Scientifico](https://scholariq.org/institutions/istituti-di-ricovero-e-cura-a-carattere-scientifico/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.